Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Ovarian Neoplasms 328Fallopian Tube Neoplasms 153Carcinoma, Ovarian Epithelial 115Endometrial Neoplasms 95Uterine Cervical Neoplasms 80Neoplasms 28Breast Neoplasms 27Peritoneal Neoplasms 24Brenner Tumor 24Carcinoma, Non-Small-Cell Lung 21Stomach Neoplasms 18Recurrence 17Neoplasm Metastasis 14Uterine Neoplasms 13Testicular Neoplasms 11Parkinson Disease 4, Autosomal Dominant Lewy Body 11Colorectal Neoplasms 11Squamous Cell Carcinoma of Head and Neck 10Lung Neoplasms 10Melanoma 9Testicular Germ Cell Tumor 8Central Nervous System Neoplasms 8Urinary Bladder Neoplasms 7Triple Negative Breast Neoplasms 7Esophageal Neoplasms 7Carcinoma 7Prostatic Neoplasms 6Pancreatic Neoplasms 6Neurotoxicity Syndromes 6Carcinosarcoma 6

Interventions

Taxes 1Specimen Handling 1Paclitaxel 1Nivolumab 1Magnetic Resonance Spectroscopy 1Ipilimumab 1Immunoglobulin G 1Gemcitabine 1Docetaxel 1Disulfides 1Carboplatin 1CTLA-4 Antigen 1Bevacizumab 1Axitinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Adenocarcinoma, Mucinous × Paclitaxel × Gynecologic × Clear all
NCT00565851 2025-12-30

Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer

National Cancer Institute (NCI)

Phase 3 Active not recruiting
1,052 enrolled 27 charts
Gynecologic

Brenner Tumor, Carcinoma, Adenocarcinoma, Mucinous, Fallopian Tube Neoplasms, Ovarian Neoplasms, Adenocarcinoma, Clear Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡